Fabtech Technologies FY26 Consolidated Income ₹431 Cr, PAT ₹38 Cr
Fabtech Technologies Limited reported FY26 consolidated total income of ₹431.33 Crore and PAT of ₹38.36 Crore. The order book exceeds ₹900 Crore. Q4 income grew 22% to ₹168.24 Crore with a net profit of ₹22.06 Crore. The company secured approximately ₹230 Crore in strategic equity infusion.
The results show growth and strategic positioning, which could positively influence investor confidence. However, the impact is moderate as margins were influenced by external disruptions and strategic investments.
The company reported a resilient performance with increased total income, a strong order book, and a net profit in Q4, indicating positive financial health and strategic progress.
Fabtech Technologies Limited (FTL) announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reported a resilient performance, reinforcing its strategic positioning as a global life science infrastructure platform.
For the full year FY26, FTL's consolidated total income stood at ₹431.33 Crore, with an order book exceeding ₹900 Crore. The company reported an EBITDA of ₹55.56 Crore, resulting in an EBITDA margin of 12.88%. Profit After Tax (PAT) for FY26 was ₹38.36 Crore, with PAT margins at 8.89%. Margins were influenced by external disruptions and strategic investments in future capacity creation.
Key business highlights for FY26 include a strong order book with expected improved execution momentum starting FY27. FTL is building a unified operating model across India, UAE, and Saudi Arabia, and is transitioning towards a "local execution" model in GCC and African markets. Management expects a gradual margin expansion trajectory to approximately 9.9% –10.5% in FY27, supported by operating leverage and scale benefits. The company is also actively evaluating strategic acquisition opportunities to strengthen its capabilities and expand its global footprint.
On a year-on-year basis, total income increased to ₹431.33 Crore from ₹335.94 Crore. Operational Profit stood at ₹36.6 Cr in FY26 compared to ₹31.27 Cr in FY25, after adjusting for exceptional items. The company ended the year strongly, with Q4 income up 22% to ₹168.24 Crore and a net profit of ₹22.06 Crore.
Fabtech Technologies continues to position itself as a critical enabler of global healthcare infrastructure, supporting the production of life-saving medicines worldwide. The company has a strengthened balance sheet and a growing global presence, with strategic equity infusion of approximately ₹230 Crore in FY26.
What to do with a filing like this
Fabtech Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fabtech Technologies Limited. Read the original for the full detail.